Status: Recruiting
A Trial to Investigate Safety, Exposure, and Efficacy of HU6 Compared With Placebo in Adult Participants With Metabolic Dysfunction-associated Steatohepatitis (MASH)
Rivus Pharmaceuticals. Inc. is sponsoring this research study to assess the safety and tolerability of HU6 as a possible treatment for patients diagnosed with metabolic dysfunction-associated steatohepatitis (MASH). The study will also assess safety, pharmacokinetics (PK) and changes in liver fat content related to patients diagnosed with MASH.
Participants needed: 180
Trial details
Phase: Phase 2Age: 30+Biological sex: AllType: InterventionalSponsor: Rivus Pharmaceuticals, Inc.Updated: May 18, 2026Locations: 31
Eligibility criteria
Male and female ≥30 years of age at time of signing the informed consent. [+3]
Have acute or chronic hepatitis, signs, and symptoms of any other liver disease... [+16]